1. Home
  2. ALLO vs PMTS Comparison

ALLO vs PMTS Comparison

Compare ALLO & PMTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • PMTS
  • Stock Information
  • Founded
  • ALLO 2017
  • PMTS 2007
  • Country
  • ALLO United States
  • PMTS United States
  • Employees
  • ALLO N/A
  • PMTS N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • PMTS Finance Companies
  • Sector
  • ALLO Health Care
  • PMTS Finance
  • Exchange
  • ALLO Nasdaq
  • PMTS Nasdaq
  • Market Cap
  • ALLO 231.9M
  • PMTS 203.1M
  • IPO Year
  • ALLO 2018
  • PMTS 2015
  • Fundamental
  • Price
  • ALLO $1.05
  • PMTS $15.18
  • Analyst Decision
  • ALLO Strong Buy
  • PMTS Strong Buy
  • Analyst Count
  • ALLO 10
  • PMTS 4
  • Target Price
  • ALLO $8.88
  • PMTS $34.00
  • AVG Volume (30 Days)
  • ALLO 5.8M
  • PMTS 81.8K
  • Earning Date
  • ALLO 08-13-2025
  • PMTS 08-08-2025
  • Dividend Yield
  • ALLO N/A
  • PMTS N/A
  • EPS Growth
  • ALLO N/A
  • PMTS N/A
  • EPS
  • ALLO N/A
  • PMTS 1.11
  • Revenue
  • ALLO N/A
  • PMTS $502,361,000.00
  • Revenue This Year
  • ALLO N/A
  • PMTS $14.61
  • Revenue Next Year
  • ALLO $199.63
  • PMTS $12.49
  • P/E Ratio
  • ALLO N/A
  • PMTS $13.72
  • Revenue Growth
  • ALLO N/A
  • PMTS 14.31
  • 52 Week Low
  • ALLO $0.86
  • PMTS $12.52
  • 52 Week High
  • ALLO $3.78
  • PMTS $35.19
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 38.79
  • PMTS 32.34
  • Support Level
  • ALLO $0.99
  • PMTS $15.01
  • Resistance Level
  • ALLO $1.21
  • PMTS $16.16
  • Average True Range (ATR)
  • ALLO 0.10
  • PMTS 1.06
  • MACD
  • ALLO -0.01
  • PMTS -0.12
  • Stochastic Oscillator
  • ALLO 20.59
  • PMTS 33.17

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

About PMTS CPI Card Group Inc.

CPI Card Group Inc is a payment technology company engaged in providing financial payment card solutions and services. It offers credit, debit, and prepaid cards. The business segments of the group are Debit and Credit, which produces Financial Payment Cards and provides integrated card services to card-issuing banks in the United States, and Prepaid Debit, which provides integrated card services to Prepaid Debit Card program managers in the United States and Others. It derives key revenue from the Debit and Credit segment.

Share on Social Networks: